Jefferies Comments On ViroPharma's Cinryze Approval In Europe

According to Jefferies, VitoPharma (NASDAQ:

) announced that the European Medicines Agency approved Cinryze in Europe for the treatment of hereditary angioedema (

). Jefferies said that it remains confident in $400m+ U.S. Cinryze prophylactic HAE sales by 2015. “Cetor is only selling in a few European countries and we believe it has generated minimal sales, whereas with a broad European label, we continue to believe there could be upside to our peak sales estimate of $68m in international Cinryze sales by 2016, even with an expected European price for Cinryze that is 40-50% of the U.S. price.” VitoPharma closed yesterday at $17.54.